Sept 24 (Reuters) – Merck said on Thursday its drug met the main goal in a mid- to late-stage trial testing it in adult patients with a type of disease that affects blood vessels at the back of the eye.
(Reporting by Christy Santhosh in Bengaluru; Editing by Sahal Muhammed)
Brought to you by www.srnnews.com
SRN News — View the original story at SRNNews.com.
